Getinge appointed Stacy Beske as President Acute Care Therapies and Executive Team member in December 2026. She brings over 20 years of medtech leadership experience across image guided therapy, diabetes, electrophysiology, diagnostics and cardiovascular care.
Her cardiology research background and prior responsibility for Philips’ Image Guided Therapy Devices unit point to deep clinical and operational insight directly linked to Getinge’s Acute Care Therapies portfolio.
We will look at how Getinge’s investment narrative around recurring revenue and margin progress could be influenced by Stacy Beske’s appointment.
Scan how Getinge’s leadership shift compares with other medtech opportunities by zeroing in on list of solid balance sheet and fundamentals (188 results) that could handle market shocks more resiliently.
Getinge Investment Narrative Recap
To own Getinge, you need to believe the shift toward recurring, higher margin offerings can keep supporting earnings quality while quality remediation costs gradually ease. Acute Care Therapies is central to that story. Stacy Beske’s appointment looks directionally helpful for execution, but by itself it does not materially change the near term picture.
The analyst consensus narrative on Simply Wall St still flags the biggest short term swing factor as execution on reducing roughly SEK 800m of extraordinary quality related costs and finalizing cardiopulmonary and cardiac assist remediation. Tariffs, inflation in contracts with fixed pricing, and a challenging China backdrop remain the main operational risks that could pressure margins.
With no fresh company announcements beyond Beske’s hire, the most relevant reference point remains management’s plan to phase out those extraordinary quality related expenses by the end of 2028. If that pathway is delivered, it would leave Getinge with a cleaner expense base and supports the focus on adjusted EBITA margins in Acute Care Therapies and across the group.
Beske’s cardiology and image guided therapy background lines up with priorities inside Acute Care Therapies, including extracorporeal support and cardiopulmonary devices that have been part of the remediation effort. For you as a shareholder, the link to catalysts is practical execution. Strong leadership in this division could help keep remediation on track while balancing tariff and cost pressures against the growing recurring revenue mix.
Getinge’s current analyst storyline points to revenues of SEK 40.9b and earnings of SEK 4.1b by 2029, built on 5.9% yearly top line growth and an earnings increase of SEK 1.3b from SEK 2.8b today.
Read More: How Investors May Respond To Getinge (OM:GETI B) Acute Care Leadership

